A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver

Trial Profile

A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Melphalan (Primary) ; Antineoplastics
  • Indications Liver metastases
  • Focus Registrational; Therapeutic Use
  • Sponsors Delcath Systems
  • Most Recent Events

    • 29 Mar 2018 According to a Delcath systems media release, results from this were presented at the 2018 Society of Surgical Oncology Annual Cancer Symposium (SSO)
    • 09 Dec 2015 According to a Delcath media release, results from this trial were published in Annals of Surgical Oncology.
    • 09 Dec 2015 Results were published in a Delcath Systems media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top